Getinge (OTCMKTS:GNGBY) Reaches New 12-Month High – What’s Next?

Getinge (OTCMKTS:GNGBY) reached a new 52-week high on Friday . The company traded as high as $25.98 and last traded at $25.98, with a volume of 105 shares trading hands. The stock had previously closed at $25.80.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Getinge from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. According to MarketBeat, Getinge has an average rating of “Strong Buy”.

Getinge Stock Performance

The business’s 50-day simple moving average is $23.24 and its two-hundred day simple moving average is $21.65. The company has a quick ratio of 0.74, a current ratio of 1.31 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.01 billion, a price-to-earnings ratio of 24.51 and a beta of 0.92.

Getinge (OTCMKTS:GNGBY) last announced its quarterly earnings results on Friday, July 17th. The company reported $0.38 earnings per share for the quarter. The firm had revenue of $894.87 million during the quarter. Getinge had a return on equity of 11.12% and a net margin of 7.81%. As a group, sell-side analysts expect that Getinge will post 1.38 earnings per share for the current fiscal year.

About Getinge

Getinge AB is a global medical technology company that develops, manufactures and markets products and systems for hospitals and life sciences institutions. The company’s offerings focus on critical care, surgical workflows and infection control, aiming to improve clinical outcomes and operational efficiency. Getinge’s solutions support a range of applications from intensive care and cardiovascular treatments to sterile reprocessing of surgical instruments.

The company’s product portfolio includes sterilization and disinfection equipment, surgical tables and lights, ventilation systems, heart-lung machines and extracorporeal membrane oxygenation (ECMO) devices.